Biotechnology Jobs

• USA - Pennsylvania - Upper Providence
• Hybrid · 2–3 days in office
• US$221,925 – US$369,875 pa
• Director · manages people

Leads a global oncology labelling team, managing the labelling process from early development through lifecycle management and ensuring regulatory compliance. Serves on the Global Labelling Committee, advises senior R&D, Safety, Regulatory and Commercial leaders, and engages regulatory authorities on labelling standards and policy.

• Belgium-Wavre
• Hybrid · 2–3 days in office
• €141,750 – €236,250 pa
• Director · manages people

Leads a global oncology labelling team, managing the labelling process from early development through lifecycle management and ensuring regulatory compliance. Serves on the Global Labelling Committee, advises senior R&D, Safety, Regulatory and Commercial leaders, and engages with regulatory authorities on labelling standards and policy.

• USA - Pennsylvania - Upper Providence
• On-site
• US$284,250 – US$473,750 pa
• Director

Leads clinical development of GU oncology assets, designing and executing Phase 1-3 interventional trials and serving as a core member of the Clinical Matrix Team. Provides real-time medical monitoring, safety data review with pharmacovigilance, and authors clinical study reports and regulatory responses. Builds key external expert relationships and contributes to business development diligence.

• USA - Pennsylvania - Upper Providence
• On-site
• US$284,250 – US$473,750 pa
• Director · manages people

Senior physician leader providing medical oversight, safety monitoring and clinical data interpretation across sarcoma oncology studies, from protocol design through regulatory interactions. Serves as a senior member of the Clinical Matrix Team, mentoring Medical Directors and engaging external experts, advisory boards and health authorities.

Real World Evidence (RWE)

• Stevenage
• Hybrid
• £119,250 – £198,750 pa
• Director

Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late pre-candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work across small molecules, biologics and antibody drug conjugates, applying AI/ML and quantitative systems pharmacology methods. Presents and defends modelling outcomes to governance boards and regulators, and contributes to protocols, analysis plans and submissions.

NONMEM · R

• Waltham, United States
• Hybrid
• £188,100 – £313,500 pa
• Director

Leads model-informed drug development for oncology programs, defining and executing model-based strategies from late discovery through lifecycle management. Conducts population PK, exposure-response, simulation-based trial design and dose selection, applying AI/ML, quantitative systems pharmacology and model-based meta-analysis. Presents to governance boards and regulators and works across matrix teams on small molecules, biologics and antibody drug conjugates.

NONMEM · R

• London
• Hybrid
• £119,250 – £198,750 pa
• Director

Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work, applying AI/ML and quantitative systems pharmacology methods, and defends results to governance boards and regulators. Sits within Oncology Translational Medicine's Clinical Pharmacology Modelling and Simulation group, working across small molecules, biologics and antibody drug conjugates.

NONMEM · R

• Belgium-Wavre
• Hybrid
• €119,250 – €198,750 pa
• Director

Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work, applying AI/ML, quantitative systems pharmacology and model-based meta-analysis to small molecules, biologics and antibody drug conjugates. Presents and defends modelling outcomes to governance boards and regulators, and contributes to protocols, analysis plans and submissions.

NONMEM · R

• USA - Pennsylvania - Upper Providence
• Hybrid
• US$188,100 – US$313,500 pa
• Director

Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work across small molecules, biologics and antibody drug conjugates, applying AI/ML and quantitative systems pharmacology methods. Presents and defends modelling outcomes to governance boards and regulators, and contributes to protocols, analysis plans and submissions.

NONMEM · R

• Durham Blackwell Street
• Hybrid
• US$188,100 – US$313,500 pa
• Director

Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work, applying AI/ML and quantitative systems pharmacology methods, and defends results to governance boards and regulators. Sits within a matrixed Clinical Pharmacology Modelling and Simulation group working across small molecules, biologics and antibody drug conjugates.

NONMEM · R

• Waltham, United States
• Hybrid · 2 days in office
• US$284,250 – US$473,750 pa
• Director · manages people

Leads a team of early clinical development medical directors and clinical scientists, owning Phase I/II clinical development plans including first-in-human, dose-escalation and proof-of-concept studies in lung and head/neck cancers. Bridges preclinical discovery and clinical development, driving translational and biomarker strategy, regulatory submissions and cross-functional matrix teams.

AI/ML

• Stevenage
• Hybrid · 2 days in office
• US$284,250 – US$473,750 pa
• Director · manages people

Leads a team of medical directors and clinical scientists designing and executing early-phase oncology trials, including first-in-human, dose-escalation and proof-of-concept studies, while bridging preclinical discovery and clinical development. Accountable for clinical development plans, benefit-risk, regulatory submissions and translational biomarker strategy across lung and head/neck cancer assets.

AI/ML

• Zug, Switzerland
• Hybrid · 2 days in office
• US$284,250 – US$473,750 pa
• Director · manages people

Leads a team of early clinical development medical directors and clinical scientists, owning Phase I/II clinical development plans including first-in-human, dose-escalation and proof-of-concept studies in lung and head/neck cancers. Bridges preclinical discovery and clinical development, driving translational and biomarker strategy with cross-functional and regulatory partners.

AI/ML

• London
• Hybrid · 2 days in office
• US$284,250 – US$473,750 pa
• Director · manages people

Leads a team of medical directors and clinical scientists designing and executing early-phase oncology trials, including first-in-human and proof-of-concept studies, while bridging preclinical discovery and clinical development. Accountable for clinical development plans, translational and biomarker strategy, and regulatory submissions across a lung and head/neck cancer portfolio.

AI/ML

• USA - Pennsylvania - Upper Providence
• Hybrid · 2 days in office
• US$284,250 – US$473,750 pa
• Director · manages people

Leads a team of medical directors and clinical scientists designing and executing early-phase oncology trials, including first-in-human and proof-of-concept studies, while bridging preclinical discovery and clinical development. Accountable for clinical development plans, translational and biomarker strategy, and regulatory submissions across lung and head/neck cancer programmes.

AI/ML · Real World Evidence